Rapt Therapeutics Inc.
RAPT Therapeutics Reports Decreased Q3 Loss and Announces Workforce Reduction
Summary
RAPT Therapeutics, Inc. reported a net loss of $18.4 million for the third quarter of 2024, a decrease from $31.4 million in the same period of 2023. The company's research and development expenses decreased to $13.3 million from $27.0 million, while general and administrative expenses decreased slightly to $6.4 million from $6.9 million. RAPT also announced a workforce reduction on July 16, 2024, affecting 47 employees, which resulted in $0.9 million in restructuring charges. As of September 30, 2024, the company had cash and cash equivalents of $97.9 million.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement